Use of the Auto-inflammatory Disease Activity Index to monitor disease activity in patients with colchicine-resistant Familial Mediterranean Fever, Mevalonate Kinase Deficiency, and TRAPS treated with canakinumab

•AIDAI is a tool for the assessment of disease activity as reported by patients or parents/guardians across a wide spectrum of auto- inflammatory diseases, it provides information complementary to the physician's clinical assessment and measurements of biomarkers.•This study uses AIDAI to assess evolution of disease activity in patients with crFMF, MKD, or TRAPS treated with canakinumab in a phase III study. The results are compared with clinical and serological assessments of disease activity, and disease-specific cut-off AIDAI values for inactive disease are calculated using a ROC analysis, together with sensitivity and specificity parameter.•This study provides an empirical basis and appropriate cut-off values for using AIDAI to assess disease activity and well-being of patients with crFMF, MKD, and TRAPS. The AIDAI can be used in clinical practice to monitor the evolution of patients and the effect of medications.